Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- Nature IndexSCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- NEW ENGLAND JOURNAL OF MEDICINE386(4) · pp.351 · 2022
- 피인용
- Web of Science 836Scopus 945
- FWCI (Scopus)
- 86.96
- JCR IF
- JCR 2021 176.082
- ISSN
- 0028-4793
저자
- Tilly, Herve제1저자교신저자Ctr Henri Becquerel, Dept Hematol, Rouen, France
- Morschhauser, FranckUniv Lille, Ctr Hosp Univ CHU Lille, ULR 7365 GRITA Grp Rech Sur Formes Injectables &, Lille, France
- Sehn, Laurie H.BC Canc, Ctr Lymphoid Canc, Vancouver, BC, Canada
- Friedberg, Jonathan W.Univ Rochester, Wilmot Canc Inst, Rochester, NY USA
- Trneny, M.Charles Univ Prague, Fac Med 1, Prague, Czech Republic
- Sharman, Jeff P.US Oncol Network, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
- Herbaux, CharlesCHU Montpellier, Montpellier, France
- Burke, John M.Rocky Mt Canc Ctr, Aurora, CO USA
- Matasar, MatthewMem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
- Rai, ShinyaKindai Univ, Fac Med, Dept Hematol & Rheumatol, Osaka, Japan
- Izutsu, KojiNatl Canc Ctr, Tokyo, Japan
- Mehta-Shah, NehaWashington Univ, St Louis, MO 63110 USA
- Oberic, LucieInst Univ Canc, Dept Hematol, Toulouse Oncopole, Toulouse, France
- Chauchet, AdrienCtr Hosp Reg Univ Besancon, Dept Hematol, Besancon, France
- Jurczak, WojciechMaria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland
- Song, YuqinPeking Univ Canc Hosp, Beijing, Peoples R China
- Greil, RichardParacelsus Med Univ, Salzburg Canc Res Inst, Med Dept 3, Ctr Clin Canc & Immunol Trials, Salzburg, Austria
- Mykhalska, LarysaFeofaniya Clin Hosp, Kiev, Ukraine
- Bergua-Burgues, Juan M.Hosp San Pedro de Alcantara, Caceres, Spain
- Cheung, Matthew C.Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
- Pinto, AntonioIRCCS, Hematol Oncol & Stem Cell Transplantat Unit, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy
- 신호진Pusan Natl Univ, Pusan Natl Univ Hosp, Res Inst Med Sci, Dept Internal Med,Div Hematol Oncol,Sch Med, Busan, South Korea
- Hapgood, GregPrincess Alexandra Hosp, Brisbane, Qld, Australia
- Munhoz, EduardoHosp Erasto Gaertner, Curitiba, Parana, Brazil
- Abrisqueta, PauVall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Hematol, Barcelona, Spain
- Gau, Jyh-PyngTaipei Vet Gen Hosp, Taipei, Taiwan
- Hirata, JamieGenentech Inc, San Francisco, CA 94080 USA
- Jiang, YanwenGenentech Inc, San Francisco, CA 94080 USA
- Yan, MarkF Hoffmann La Roche, Mississauga, ON, Canada
- Lee, CalvinGenentech Inc, San Francisco, CA 94080 USA
초록
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, which is ubiquitously expressed on the surface of malignant B cells. METHODS We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab vedotin, as compared with standard R-CHOP, in patients with previously untreated intermediate-risk or high-risk DLBCL. Patients 18 to 80 years of age were randomly assigned in a 1:1 ratio to receive six cycles of either pola-R-CHP or R-CHOP, plus two cycles of rituximab alone. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival and safety. RESULTS Overall, 879 patients underwent randomization: 440 were assigned to the pola-R-CHP group and 439 to the R-CHOP group. After a median follow-up of 28.2 months, the percentage of patients surviving without progression was significantly higher in the pola-R-CHP group than in the R-CHOP group (76.7% [95% confidence interval (CI), 72.7 to 80.8] vs. 70.2% [95% CI, 65.8 to 74.6] at 2 years; stratified hazard ratio for progression, relapse, or death, 0.73 by Cox regression; 95% CI, 0.57 to 0.95; P=0.02). Overall survival at 2 years did not differ significantly between the groups (88.7% [95% CI, 85.7 to 91.6] in the pola-R-CHP group and 88.6% [95% CI, 85.6 to 91.6] in the R-CHOP group; hazard ratio for death, 0.94; 95% CI, 0.65 to 1.37; P=0.75). The safety profile was similar in the two groups. CONCLUSIONS Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP.
키워드
RITUXIMAB PLUS CYCLOPHOSPHAMIDENON-HODGKIN-LYMPHOMAANTIBODY-DRUG CONJUGATEELDERLY-PATIENTSPHASE-IIIR-CHOPVINCRISTINEDOXORUBICINTRIALCHEMOTHERAPY
식별자
- Scopus EID
- 2-s2.0-85123295133
- WoS UID
- 000729947300001



로그인
연구물 목록으로